Cargando…
Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?
INTRODUCTION: Sclerostin levels have been reported to be low in ankylosing spondylitis (AS), but there is no data regarding the possible role of this Wnt inhibitor during anti-tumor necrosis factor (TNF) therapy. The present study longitudinally evaluated sclerostin levels, inflammatory markers and...
Autores principales: | Saad, Carla GS, Ribeiro, Ana CM, Moraes, Julio CB, Takayama, Liliam, Goncalves, Celio R, Rodrigues, Marcelo B, de Oliveira, Ricardo M, Silva, Clovis A, Bonfa, Eloisa, Pereira, Rosa MR |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3580528/ https://www.ncbi.nlm.nih.gov/pubmed/23062122 http://dx.doi.org/10.1186/ar4055 |
Ejemplares similares
-
IL-23/Th17 axis is not influenced by TNF-blocking agents in ankylosing spondylitis patients
por: Milanez, Fernanda Manente, et al.
Publicado: (2016) -
Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area
por: Shimabuco, Andrea Yukie, et al.
Publicado: (2020) -
Hypoparathyroidism mimicking ankylosing spondylitis and myopathy: a case report
por: Kajitani, Thayana Ribeiro, et al.
Publicado: (2011) -
Improvement of conjunctival cytological grade and tear production in Ankylosing Spondylitis patients under TNF inhibitors: a long-term follow-up
por: Usuba, Fany Solange, et al.
Publicado: (2020) -
Serum Sclerostin as a Possible Biomarker in Ankylosing Spondylitis: A Case-Control Study
por: Perrotta, Fabio Massimo, et al.
Publicado: (2018)